RBC Capital Reiterates Buy Rating for Praxis Precision Medicines, Inc.

RBC Capital has reiterated its buy rating for Praxis Precision Medicines, Inc. (NASDAQ: PRAX) as of June 18, 2026, setting a price target of $449. The stock is currently trading around $270.01, signaling confidence in the company's future prospects despite its current unprofitable status.

Other Institutional Activity in Praxis Precision Medicines, Inc.

Institutional investors are showing significant interest in Praxis. Janus Henderson Group increased its holdings by 218,777 shares, bringing its total to 3,458,863 shares valued at approximately $1.11 billion. Orbis Allan Gray Ltd made a substantial addition of 1,217,318 shares, resulting in a total of 2,472,480 shares worth about $796.6 million. BlackRock, Inc. also raised its stake by 246,429 shares to own 2,324,929 shares, valued at roughly $749.1 million.

Praxis Precision Medicines, Inc. Stock Snapshot

Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX) are trading near $270.01. The company has a market capitalization of about $7.53 billion. Despite its current lack of profitability, evidenced by a negative forward P/E ratio of -26.52, the stock has shown volatility with a 52-week range between $37.19 and $366.52. The 50-day moving average stands at $316.78, while the 200-day moving average is $244.12. The company maintains strong liquidity ratios, with a current ratio of 15.88 and a quick ratio of 15.66, and a low debt-to-equity ratio of 0.10.

Recent Earnings

Praxis Precision Medicines has yet to achieve profitability, with a negative EPS of -$13.40. The company reported no net margin and a negative return on equity of -35.32%. Investors are looking forward to the next earnings report scheduled for August 10, 2026.

Insider Buying and Selling at Praxis Precision Medicines, Inc.

On June 10, 2026, several insiders purchased shares of Praxis Precision Medicines. Mitchell Dean, William Young, and several others each bought 1,371 shares, while Jill Desimone, Stuart Arbuckle, and others acquired 648 shares each. These transactions were not part of any pre-planned trading programs.

Analysts Set New Price Targets

On June 18, 2026, RBC Capital reiterated its buy rating with a $449 price target. Earlier in June, Oppenheimer and Truist Securities maintained their buy ratings with targets of $650 and $616, respectively. Deutsche Bank also maintained a buy rating with a $374 target, while Wedbush stood out with a sell rating and a $162 target. The consensus among analysts is a strong buy, with an average target price of $627.59 based on 17 opinions.

About Praxis Precision Medicines, Inc.

Praxis Precision Medicines, Inc. is a biopharmaceutical company based in Boston, Massachusetts. Focused on therapies for central nervous system disorders, it leverages platforms like Cerebrum for small molecule therapies and Solidus for antisense oligonucleotide development. The company is working on several promising drugs, including ulixacaltamide for essential tremor and relutrigine for developmental and epileptic encephalopathies. With a team of 168 employees, Praxis is led by CEO Mr. Marcio Silva De'Souza.

Bottom Line

RBC Capital's reiterated buy rating and $449 target for Praxis Precision Medicines, Inc. highlights ongoing confidence in the company's potential. Institutional activity further underscores investor interest, though the stock remains volatile and unprofitable at present. As always, it's important to remember that analyst ratings and institutional filings are backward-looking and reflect past information.